Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Exon 8 of tumour suppressor gene
p53
was sequenced in domestic cats and showed remarkable similarity to the human sequence. Only four of the 13 nucleotide differences gave rise to interspecific amino acid differences. In an investigated
lymphosarcoma
we detected a mutation cgg --> tgg (arginine --> tryptophan) in codon no. 282.
...
PMID:Sequence of an exon of the feline p53 gene--mutation in a lymphosarcoma. 822 Oct 43
Upstream stimulating factor (USF2) is a basic helix-loop-helix leucine zipper transcription factor, which is found in most tissues. A critical role for USF2 in cellular proliferation has been proposed based on its importance in the regulation of various cyclins and
P53
and its capability to antagonize c-myc. In this paper we report that IL-3, which is a major growth factor for mast cells, induces USF2 protein synthesis in murine mast cells (MC-9). Surprisingly, it does not significantly affect the level of USF2 mRNA in these cells at any of the time points tested. Using polysomal fractionation and RNA analysis we then demonstrated that this translational regulation is mostly the result of increased USF2 translational efficiency. Moreover, protein kinase C (PKC) inhibitors prevented both the induction of USF2 protein synthesis and the increase in USF2 translational efficiency in IL-3-activated mast cells. Two other hematopoietic cell lines were used to determine whether the translational regulation of USF2 is of a more general nature: mouse
lymphosarcoma
cells whose proliferation is inhibited by dexamethasone; and mouse erythroleukemia cells that differentiate upon exposure to hexamethylen bisacetamide. In both cell types, USF2 translation was repressed in the non-dividing cells. This strongly implies that USF2 is translationally repressed in quiescent hematopoietic cells. Considering the proposed role of USF in proliferation it seems that translational regulation of USF2 might have an important role in cellular growth.
...
PMID:Growth-dependent and PKC-mediated translational regulation of the upstream stimulating factor-2 (USF2) mRNA in hematopoietic cells. 948 40
The mutations of the
p53
gene previously represented one of several genetic changes involved in the development of bovine leukemia virus (BLV)-induced
lymphosarcoma
, while the effects of these mutations on the function of
p53
are unknown. We identified four mutations of
p53
gene in BLV-infected cattle with
lymphosarcoma
and demonstrated clearly the existence of two functionally distinct groups of mutants: (i) the mutant forms with substitutions at codons 241 and 242, which were mapped within an evolutionally conserved region and corresponded to the human "hot-spot" mutations, had completely lost the capacities for transactivation and growth suppression and gained transdominant repression activity in
p53
-null SAOS-2 cells; and (ii) the mutations at codons 206 and 207 were located outside the evolutionally conserved regions. These mutants partially retained the capacity for transactivation and growth suppression and failed to inhibit the transactivation activity of coexpressed wild-type
p53
, instead showing an enhancement of this activity. In addition, protein analysis using an antibody specific for the mutant form revealed that the mutations at codons 206 and 242 induced a "mutant" conformation of the bovine
p53
proteins. Collectively, these results show that mutations of
p53
gene in BLV-infected cattle with
lymphosarcoma
can potentially alter its physiological function and may play an important role in BLV-induced leukemogenesis. Copyright 1998 Academic Press.
...
PMID:Function and Conformation of Wild-Type p53 Protein Are Influenced by Mutations in Bovine Leukemia Virus-Induced B-Cell Lymphosarcoma 952 33
The mutations of the
p53
gene previously represented one of several genetic changes involved in the development of bovine leukemia virus (BLV)-induced
lymphosarcoma
, while the effects of these mutations on the function of
p53
are unknown. We identified four mutations of
p53
gene in BLV-infected cattle with
lymphosarcoma
and demonstrated clearly the existence of two functionally distinct groups of mutants: (i) the mutant forms with substitutions at codons 241 and 242, which were mapped within an evolutionally conserved region and corresponded to the human "hot-spot" mutations, had completely lost the capacities for transactivation and growth suppression and gained transdominant repression activity in
p53
-null SAOS-2 cells; and (ii) the mutations at codons 206 and 207 were located outside the evolutionally conserved regions. These mutants partially retained the capacity for transactivation and growth suppression and failed to inhibit the transactivation activity of coexpressed wild-type
p53
, instead showing an enhancement of this activity. In addition, protein analysis using an antibody specific for the mutant form revealed that the mutations at codons 206 and 242 induced a "mutant" conformation of the bovine
p53
proteins. Collectively, these results show that mutations of
p53
gene in BLV-infected cattle with
lymphosarcoma
can potentially alter its physiological function and may play an important role in BLV-induced leukemogenesis.
...
PMID:Function and conformation of wild-type p53 protein are influenced by mutations in bovine leukemia virus-induced B-cell lymphosarcoma. 954 Jul 87
Experimental animal model of tumor progression based on mice
lymphosarcoma
(LS) and resistant
lymphosarcoma
(RLS) has been developed. LS tumor displays high sensitivity to cyclophosphamide, which is widely used in anticancer therapy. RLS tumor was derived from LS by passaging in mice receiving low concentration of cyclophosphamide (20 mg/kg) and display resistance to cyclophosphamide (up to dose 150 mg/kg). The primary cultures of LS and RLS tumors display different expression levels of the genes related to apoptosis and multiple drug-resistant phenotype: in RLS tumor high levels of mdr1b and bcl-2 genes and low level of
p53
gene expression were found. A total of 10% of cells in RLS primary culture display multiple drug-resistant phenotype and survive even at high dose of cytostatics. Cultivation of RLS primary culture in the presence of increasing vinblastine concentrations gives RLS(40) cell culture, which exhibits high levels of mdr1a/1b genes expression as compared to RLS and 20-fold increase of resistance to cytostatics. Drug-resistant RLS(40) cells were transplanted into CBA mice and sensitivity of the tumors to anticancer drugs was tested. RLS(40) tumors were resistant to a number of cytostatics used in anticancer therapy (cyclophosphamide, cysplatin, vinblastine, rubomycinum). Thus, RLS(40) tumor can be used as model, which corresponds to tumor status observed in patients after one or several courses of chemotherapy and can be useful for testing conventional therapy alone or together with newly developed gene-targeted therapeutics.
...
PMID:Animal model of drug-resistant tumor progression. 1734 38
The progress of drug resistance of RLS(40) resistant
lymphosarcoma
and specific features of toxic lesions in the liver in polychemotherapy were studied. After intramuscular injection of tumor cells, the mice received a course of polychemotherapy. The tumor material was then collected and transplanted to intact animals, after which polychemotherapy was carried out. A total of 4 passages of tumor cells and 4 polychemotherapy courses were carried out. The expression of mdr1b, bcl-2, and
p53
genes in tumor cells increased by 1.3, 2.3, and 1.6 times after 4 courses of polychemotherapy in comparison with intact tumor. Volume density of apoptoses in tumor tissue after 4 polychemotherapy courses decreased 1.7 times compared to that after single course. The increase in cytostatic load was associated with aggravation of destructive changes in the liver: the volume density of necroses in the liver increased 1.3 times after 4 passages of the tumor.
...
PMID:Morphologic changes in the tumor and liver in mice with transplanted RLS40 lymphosarcoma during increase of its drug resistance. 2111 5
To characterize the expression of P-glycoprotein (Pgp) and
p53
in different histologic grades of canine multicentric
lymphosarcoma
(
LSA
), 31 cases of
LSA
without prior treatment were studied. The expression levels of the Pgp and
p53
proteins were evaluated for their clinicopathologic significance among standard histologic evaluation. Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded archival samples of 31 previously untreated
LSA
cases to detect the expression of Pgp and
p53
. All dogs were subsequently treated with a combination chemotherapy protocol. Remission and survival durations were evaluated for correlation with histologic grade and presence of drug resistance markers. Of the 31 cases, 24 (80%) and 7 (22%) were positive for Pgp and
p53
, respectively. Overall, the median survival and duration of remission in the study was 246 days and 137 days, respectively. The National Cancer Institute working formulation histologic grade was not associated with either survival or duration of first remission (DOR). The Pgp protein expression and DOR and survival was not statistically significant. Expression of
p53
was statistically correlated with survival.
...
PMID:Clinicopathologic significance of histologic grade, pgp, and p53 expression in canine lymphoma. 2353 52